AbbVie Inc.
10/03/2024 | Press release | Distributed by Public on 10/03/2024 14:08
Business/Financial Results Form 8 K
AbbVie Inc.
Guidance Including the Impact of Acquired IPR&D and Milestones Expense
(Unaudited)
| (in millions, except per share data) | Quarter Ended September 30, 2024 | Full-Year Ended December 31, 2024 | ||||||||||
| Acquired IPR&D and Milestones Expense | Adjusted Diluted EPS Range | Acquired IPR&D and Milestones Expense | Adjusted Diluted EPS Range | |||||||||
| Low | High | Low | High | |||||||||
| Previously announced guidance excluding Q3 2024 acquired IPR&D and milestones expense | $ | - | $ | 2.92 | $ | 2.96 | $ | 1,101 | $ | 10.71 | $ | 10.91 |
| Q3 2024 acquired IPR&D and milestones expense | 82 | (0.04) | (0.04) | 82 | (0.04) | (0.04) | ||||||
|
Guidance including Q3 2024 acquired IPR&D and milestones expensea
|
$ | 82 | $ | 2.88 | $ | 2.92 | $ | 1,183 | $ | 10.67 | $ | 10.87 |
a The Company's 2024 adjusted diluted EPS guidance excludes any impact from acquired IPR&D and milestones expense that may be incurred beyond the third quarter of 2024, as both cannot be reliably forecasted.
1